Westport biotech Intensity Therapeutics has announced the completion of a $6.5 million Series B financing, which it plans to use to advance the clinical development of a cancer-treating drug.

Intensity’s lead product candidate INT230-6 is a direct intratumoral injection that is being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors.